Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Calliditas Therapeutics Presents Additional Data Analyses From Phase 3 NeflgArd Trial Of Nefecon In Primary IgA Nephropathy At ISN World Congress Of Nephrology 2024

Author: Benzinga Newsdesk | April 18, 2024 07:14am

Richard Philipson, Chief Medical Officer of Calliditas, said, "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."

Posted In: CALT


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist